Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration

J. Chandrasekhar, VC. de Winter, DN. Kalkman, S. Sartori, R. Chandiramani, MB. Aquino, P. de Wilde, D. Zeebregts, P. Woudstra, MA. Beijk, P. Hájek, B. Atzev, M. Hudec, TK. Ong, M. Mates, B. Borisov, HM. Warda, P. den Heijer, J. Wojcik, A....

. 2021 ; 35 (2) : 309-320. [pub] 20210130

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22004480
E-resources Online Full text

NLK ProQuest Central from 1999-03-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-02-01 to 1 year ago
Health & Medicine (ProQuest) from 1999-03-01 to 1 year ago

Links

PubMed 33515411
DOI 10.1007/s10557-020-07087-6
Knihovny.cz E-resources

PURPOSE: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze the performance of the COMBO stent by ACS status and ACS subtype. METHODS: The COMBO collaboration (n = 3614) is a patient-level pooled dataset from the MASCOT and REMEDEE registries. We evaluated outcomes by ACS status, and ACS subtype in patients with ST segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) versus unstable angina (UA). The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Secondary outcomes included stent thrombosis (ST). RESULTS: We compared 1965 (54%) ACS and 1649 (46.0%) non-ACS patients. ACS presentations included 40% (n = 789) STEMI, 31% (n = 600) NSTEMI, and 29% (n = 576) UA patients. Risk of 1-year TLF was greater in ACS patients (4.5% vs. 3.3%, HR 1.51 95% CI 1.01-2.25, p = 0.045) without significant differences in definite/probable ST (1.1% vs 0.5%, HR 2.40, 95% CI 0.91-6.31, p = 0.08). One-year TLF was similar in STEMI, NSTEMI, and UA (4.8% vs 4.8% vs. 3.7%, p = 0.60), but definite/probable ST was higher in STEMI patients (1.9% vs 0.5% vs 0.7%, p = 0.03). Adjusted outcomes were not different in MI versus UA patients. CONCLUSIONS: Despite the novel EPC capture technology, COMBO stent PCI was associated with somewhat greater risk of 1-year TLF in ACS than in non-ACS patients, without significant differences in stent thrombosis. No differences were observed in 1-year TLF among ACS subtypes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004480
003      
CZ-PrNML
005      
20220127145215.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10557-020-07087-6 $2 doi
035    __
$a (PubMed)33515411
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chandrasekhar, Jaya $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, USA $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
245    10
$a One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration / $c J. Chandrasekhar, VC. de Winter, DN. Kalkman, S. Sartori, R. Chandiramani, MB. Aquino, P. de Wilde, D. Zeebregts, P. Woudstra, MA. Beijk, P. Hájek, B. Atzev, M. Hudec, TK. Ong, M. Mates, B. Borisov, HM. Warda, P. den Heijer, J. Wojcik, A. Iniguez, Z. Coufal, M. Lee, JG. Tijssen, KT. Koch, U. Baber, GD. Dangas, A. Colombo, RJ. de Winter, R. Mehran, MASCOT and REMEDEE investigators (Appendix I)
520    9_
$a PURPOSE: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze the performance of the COMBO stent by ACS status and ACS subtype. METHODS: The COMBO collaboration (n = 3614) is a patient-level pooled dataset from the MASCOT and REMEDEE registries. We evaluated outcomes by ACS status, and ACS subtype in patients with ST segment elevation myocardial infarction (STEMI) or non-STEMI (NSTEMI) versus unstable angina (UA). The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization. Secondary outcomes included stent thrombosis (ST). RESULTS: We compared 1965 (54%) ACS and 1649 (46.0%) non-ACS patients. ACS presentations included 40% (n = 789) STEMI, 31% (n = 600) NSTEMI, and 29% (n = 576) UA patients. Risk of 1-year TLF was greater in ACS patients (4.5% vs. 3.3%, HR 1.51 95% CI 1.01-2.25, p = 0.045) without significant differences in definite/probable ST (1.1% vs 0.5%, HR 2.40, 95% CI 0.91-6.31, p = 0.08). One-year TLF was similar in STEMI, NSTEMI, and UA (4.8% vs 4.8% vs. 3.7%, p = 0.60), but definite/probable ST was higher in STEMI patients (1.9% vs 0.5% vs 0.7%, p = 0.03). Adjusted outcomes were not different in MI versus UA patients. CONCLUSIONS: Despite the novel EPC capture technology, COMBO stent PCI was associated with somewhat greater risk of 1-year TLF in ACS than in non-ACS patients, without significant differences in stent thrombosis. No differences were observed in 1-year TLF among ACS subtypes.
650    _2
$a akutní koronární syndrom $x klasifikace $x komplikace $x mortalita $x chirurgie $7 D054058
650    _2
$a nestabilní angina pectoris $x komplikace $7 D000789
650    _2
$a koronární trombóza $x epidemiologie $7 D003328
650    _2
$a stenty uvolňující léky $x škodlivé účinky $x statistika a číselné údaje $7 D054855
650    _2
$a endoteliální progenitorové buňky $x metabolismus $7 D066026
650    _2
$a lidé $7 D006801
650    _2
$a infarkt myokardu $x klasifikace $x komplikace $7 D009203
650    _2
$a koronární angioplastika $x metody $7 D062645
650    _2
$a protézy - design $7 D011474
650    _2
$a rizikové faktory $7 D012307
650    _2
$a sirolimus $x aplikace a dávkování $7 D020123
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
700    1_
$a de Winter, Vera C $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Kalkman, Deborah N $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Sartori, Samantha $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, USA
700    1_
$a Chandiramani, Rishi $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, USA
700    1_
$a Aquino, Melissa B $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, USA
700    1_
$a de Wilde, Puk $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Zeebregts, Doreen $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Woudstra, Pier $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Beijk, Marcel A $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Hájek, Petr $u Department of Cardiology, Motol University Hospital, Prague, Czech Republic
700    1_
$a Atzev, Borislav $u Department of Cardiology, University Hospital St. Ekaterina, Sofia, Bulgaria
700    1_
$a Hudec, Martin $u Department of Cardiology, SUSCCH, a.s. Banska Bystrica, Banska Bystrica, Slovakia
700    1_
$a Ong, Tiong Kiam $u Department of Cardiology, Sarawak Heart Centre, Kota Samarahan, Sarawak, Malaysia
700    1_
$a Mates, Martin $u Department of Cardiology, Nemocnice na Homolce - Kardiologie, Prague, Czech Republic
700    1_
$a Borisov, Borislav $u Department of Cardiology, MBAL St. Ivan Rilski, Dupnitsa, Bulgaria
700    1_
$a Warda, Hazem M $u Department of Cardiology, Alhyatt Cardiovascular Center, Alexandria, and Tanta University Hospital, Tanta, Egypt
700    1_
$a den Heijer, Peter $u Department of Cardiology, Breda Amphia, Breda, Netherlands
700    1_
$a Wojcik, Jaroslaw $u Hospital of Invasive Cardiology IKARDIA, Nałęczów, Lublin, Poland
700    1_
$a Iniguez, Andres $u Department of Cardiology, Hospital Álvaro Cunqueiro, Vigo, Spain
700    1_
$a Coufal, Zdeněk $u Department of Cardiology, T. Bata Regional Hospital Zlin, Zlin, Czech Republic
700    1_
$a Lee, Michael $u Department of Cardiology, Queen Elizabeth Hospital, Kowloon, Hong Kong
700    1_
$a Tijssen, Jan G $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Koch, Karel T $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Baber, Usman $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, USA
700    1_
$a Dangas, George D $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, USA
700    1_
$a Colombo, Antonio $u Department of Cardiology, San Raffaele Hospital, Milan, Italy
700    1_
$a de Winter, Robbert J $u Department of Clinical and Experimental Cardiology, Amsterdam UMC, Heart Center, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands
700    1_
$a Mehran, Roxana $u The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, USA. roxana.mehran@mountsinai.org $u Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA. roxana.mehran@mountsinai.org
710    2_
$a MASCOT and REMEDEE investigators (Appendix I)
773    0_
$w MED00001057 $t Cardiovascular drugs and therapy $x 1573-7241 $g Roč. 35, č. 2 (2021), s. 309-320
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33515411 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145211 $b ABA008
999    __
$a ok $b bmc $g 1751825 $s 1155629
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 35 $c 2 $d 309-320 $e 20210130 $i 1573-7241 $m Cardiovascular drugs and therapy $n Cardiovasc Drugs Ther $x MED00001057
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options